Latest Breaking News On - Susi teichmann - Page 1 : comparemela.com

DIFICLIRTM (fidaxomicin) is now recommended as first-line CDI treatment in both European and U.S. guidelines1,2 Significantly fewer patients in the fidaxomicin group than the vancomycin group

United statesUnited kingdomMark wilcoxKostenloser wertpapierhandelVan prehnSusi teichmannTillotts pharmaAdrian hillAntimicrob chemotherJapanese zeria groupClinical study groupSociety for healthcare epidemiology of americaInfectious disease society of americaLeeds teaching hospitals university ofHead of international operationsCorporate communications